World Cancer Day 2026: A Focus on Prevention and Raising Treatment Bars

World Cancer Day is an international awareness day marked every year on February 4 to raise awareness about cancer and to mobilize action.

The theme of this year’s World Cancer Day 2026 is “United by Unique.”

In a statement, the World Health Organization (WHO) explained that the theme “reminds us that while cancer is a global threat, each country, each community and each person affected by cancer faces distinct realities. Effective responses must therefore be shaped collectively and implemented locally.”

Created by the Union for International Cancer Control (UICC), World Cancer Day was established in 2000.

UICC leads global actions across 170 countries, such as community-led vaccination initiatives, educational series and support networks. Its stated goals are to raise awareness about cancer, encourage its prevention and mobilize action to address the global cancer epidemic.

Cancer remains one of the world’s leading causes of death. According to the WHO, there were an estimated 20 million new cancer cases and nearly 10 million cancer deaths worldwide in 2020.

Cancer incidence is expected to rise sharply over the coming decades as populations age and exposure to risk factors increases. Lifestyle factors and persistent inequities in access to care are other significant drivers.

The WHO projects that annual cancer cases could reach more than 35 million by 2050, representing a nearly 80% increase compared with 2020 levels, with the fastest growth occurring in low- and middle-income countries.

The most common causes of cancer death in 2020 were lung, colon and rectum, liver, stomach and breast cancers.

According to the global healthy agency, between 30% and 50% of cancers can be prevented by avoiding risk factors and implementing current evidence-based prevention strategies. Cancer burden can also be reduced through early detection and timely, appropriate treatment and care. Many cancers have a high chance of cure if diagnosed early and treated appropriately, says the WHO.

WHO Says Four in Ten Cancer Cases are Preventable

Ahead of World Cancer Day, the WHO shared findings from a global analysis it conducted in conjunction with its International Agency for Research on Cancer (IARC), which revealed that up to four in every 10 cancer cases around the world could be prevented.

The analysis found that this could be achieved by addressing modifiable risk factors such as tobacco use, alcohol, high body mass index, air pollution, physical inactivity and certain infections.

The study, covering data from 185 countries and 36 cancer types, estimates that roughly 7.1 million of the 18.7 million new cancer cases (about 37%) in 2022 were linked to these preventable causes, with tobacco responsible for the largest share (15%), followed by infections (10%) and alcohol consumption (3%). Lung, stomach and cervical cancers accounted for nearly half of all potentially avoidable cases.

The WHO advised that “the findings underscore the need for context-specific prevention strategies that include strong tobacco control measures, alcohol regulation, vaccination against cancer-causing infections such as human papillomavirus (HPV) and hepatitis B, improved air quality, safer workplaces and healthier food and physical activity environments.”

It encourages coordinated action across sectors, from health and education to energy, transport and labour to help “prevent millions of families from experiencing the burden of a cancer diagnosis.”

Additionally, the health agency said “addressing preventable risk factors not only reduces cancer incidence but also lowers long-term health-care costs and improves population health and well-being.”

A Focus on Cancer Prevention

Early diagnosis is one of the most effective ways to reduce cancer mortality, as cancers detected at an earlier stage are far more likely to be treated successfully and with less intensive therapy.

Population-based screening programs have been shown to significantly improve outcomes for several common cancers, including breast cancer through mammography, cervical cancer through HPV testing and Pap smears, colorectal cancer through fecal testing and colonoscopy and lung cancer through low-dose CT scans in high-risk individuals such as long-term smokers.

These screening tools help identify cancer or pre-cancerous changes before symptoms appear, enabling earlier intervention, improved survival rates and lower healthcare costs.

HPV vaccination also plays a critical preventive role by dramatically reducing the risk of cervical cancer and other HPV-related cancers, complementing screening efforts and helping shift cancer control upstream.

Expanding access to evidence-based screening, alongside advances in imaging, biomarkers and liquid biopsies, remains a critical pillar of global cancer control efforts.

The Cancer Treatment Landscape in 2026

The oncology landscape in 2026 looks very different from even a decade ago. Precision medicine, next-generation sequencing and biomarker-driven therapies are now central to cancer care.

Immunotherapies and targeted treatments continue to expand into earlier lines of therapy and new tumor types, while advances in radiotherapy, cell therapies and antibody-drug conjugates (ADCs) are pushing survival curves in the right direction.

Liquid biopsies, AI-enabled imaging and real-world data are improving early detection and disease monitoring, offering the potential to catch cancers sooner, when outcomes are far better.

Notable Recent Oncology Drug Approvals

The latest wave of oncology approvals has continued to skew toward high-impact combination regimens, expanded label breadth for platform drugs and more targeted options in biomarker-defined disease.

To kick off 2026, the FDA approved Johnson & Johnson’s Darzalex Faspro (daratumumab and hyaluronidase-fihj) with VRd (bortezomib, lenalidomide and dexamethasone) for newly diagnosed multiple myeloma patients who are ineligible for autologous stem cell transplant. Dubbed the “quaddruplet regimen,” the treatment is being touted by the company as a potential new standard of care. The approval is the 12th indication for Darzalex Faspro and the 5th in newly diagnosed multiple myeloma.

Also in January, Roche’s subcutaneous Lunsumio Velo (mosunetuzumab) got the green light from the FDA for relapsed or refractory (R/R) follicular lymphoma in patients who have previously received two or more lines of systemic therapy. The subcutaneous formulation of the bispecific CD20-CD3 antibody offers a dramatic reduction in administration time, from the two to four hours that traditional IV formulations take to just one minute.

In December 2025, the FDA approved a combination subcutaneous formulation consisting of Faspro (hyaluronidase-lpuj) and Janssen’s Rybrevant (amivantamab) for adult patients across all indications approved for the IV formulation of amivantamab.

In November 2025, the FDA granted traditional (full) approval to Amgen’s Imdelltra (tarlatamab-dlle) for adults with extensive-stage small cell lung cancer (ES-SCLC) who have progressed on or after platinum-based chemotherapy. Previously granted accelerated approval in May 2024, this, the first bispecific T-cell engager for a solid tumor, is now fully approved based on improved overall survival data.

Merck & Co.’s PD-1 inhibitor Keytruda (pembrolizumab) remains the benchmark blockbuster immunotherapy globally, with the company reporting 2024 sales growth to about $29.5 billion. It has garnered approvals in 42 indications across 18 different types of cancer since its 2014 approval for unresectable melanoma.

In December 2025, it was approved in combination with Pfizer and Astellas’ Padcev (enfortumab vedotin-ejfv) as neoadjuvant and adjuvant therapy in adults with muscle-invasive bladder cancer (MIBC) unable to receive cisplatin-based chemotherapy.

Its approvals cover a wide range of solid tumors and blood cancers, from melanoma, non-small cell lung cancer (NSCLC), head and neck cancer, triple-negative breast cancer to various gastrointestinal, gynecological and urological cancers.

In hematologic malignancies, Darzalex (daratumumab) remains a foundational multiple myeloma franchise. Genmab reported worldwide 2024 net sales of about $11.67 billion (as reported by J&J) for the anti-CD38 monoclonal antibody.

ADCs and next-gen formulations are also finding their footing, moving earlier in disease and into combination regimens. Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) and Roche’s Perjeta (pertuzumab) pairing won a first-line FDA approval in HER2+ metastatic breast cancer in January this year.